Skip to main content

D3 Bio Closes $200 Million Series A to Develop Best-in-Class Precision Medicines

D3 Bio, a Shanghai startup, raised an impressive $200 million in a Series A financing from well-known China investors with the goal of developing best-in-class precision medicines. The company plans to examine clinical records to find medications with disappointing efficacy, develop more effective treatments and then bring them to global markets. The Series A funding included Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec’s Corporate Venture Fund, among others. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.